澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨

路透中文06-25 19:49

BUZZ-澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨

6月25日 - ** 生物技术公司Vivani Medical VANI.O 股价在盘前交易中上涨6%，至1.29美元

** 该公司表示，澳大利亚伦理委员会已批准其肥胖症药物植入物NPM-139的早期临床试验，该产品旨在随时间推移持续缓释药物

** 称该试验将在20名成年受试者中进行，为期4周，旨在比较低剂量司美格鲁肽植入剂与Wegovy的疗效

** 该试验将针对肥胖患者测试该植入剂，肥胖是一种因体内脂肪过多而增加患糖尿病和心脏病等疾病风险的病症

** 公司表示，试验的主要目标是评估安全性及药物在体内的代谢情况，同时也会追踪体重减轻情况

** 试验将于2026年年中启动；将根据结果筹备规模更大的后续研究

** 截至上一交易日收盘，该股年内累计跌幅约为1%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646877499?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-25 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646877499","market":"us","top_or_hot":-1,"title":"澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨</title></head><body><p><span>6月25日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司Vivani Medical <span>VANI.O</span> 股价在盘前交易中上涨6%，至1.29美元 </p><p>** 该公司表示，澳大利亚伦理委员会已批准其肥胖症药物植入物NPM-139的早期临床试验，该产品旨在随时间推移持续缓释药物</p><p>** 称该试验将在20名成年受试者中进行，为期4周，旨在比较低剂量司美格鲁肽植入剂与Wegovy的疗效</p><p>** 该试验将针对肥胖患者测试该植入剂，肥胖是一种因体内脂肪过多而增加患糖尿病和心脏病等疾病风险的病症</p><p>** 公司表示，试验的主要目标是评估安全性及药物在体内的代谢情况，同时也会追踪体重减轻情况</p><p>** 试验将于2026年年中启动；将根据结果筹备规模更大的后续研究</p><p>** 截至上一交易日收盘，该股年内累计跌幅约为1%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-06-25 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨</title></head><body><p><span>6月25日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司Vivani Medical <span>VANI.O</span> 股价在盘前交易中上涨6%，至1.29美元 </p><p>** 该公司表示，澳大利亚伦理委员会已批准其肥胖症药物植入物NPM-139的早期临床试验，该产品旨在随时间推移持续缓释药物</p><p>** 称该试验将在20名成年受试者中进行，为期4周，旨在比较低剂量司美格鲁肽植入剂与Wegovy的疗效</p><p>** 该试验将针对肥胖患者测试该植入剂，肥胖是一种因体内脂肪过多而增加患糖尿病和心脏病等疾病风险的病症</p><p>** 公司表示，试验的主要目标是评估安全性及药物在体内的代谢情况，同时也会追踪体重减轻情况</p><p>** 试验将于2026年年中启动；将根据结果筹备规模更大的后续研究</p><p>** 截至上一交易日收盘，该股年内累计跌幅约为1%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nL4S42X14R:1","article_id":"2646877499","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646877499","pubTimestamp":1782388180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨6月25日-** 生物技术公司Vivani MedicalVANI.O股价在盘前交易中上涨6%，至1.29美元** 该公司表示，澳大利亚伦理委员会已批准其肥胖症药物植入物NPM-139的早期临床试验，该产品旨在随时间推移持续缓释药物** 称该试验将在20名成年受试者中进行，为期4周，旨在比较低剂量司美格鲁肽植入剂与Wegovy","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4082":"医疗保健设备","VANI":"Vivani Medical, Inc."},"translate_title":"Vivani shares rise as Australia approves clinical trial of obesity drug implant","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VANI":0.9},"content_text":"BUZZ-澳大利亚批准肥胖症药物植入物临床试验，Vivani股价应声上涨6月25日 - ** 生物技术公司Vivani Medical VANI.O 股价在盘前交易中上涨6%，至1.29美元 ** 该公司表示，澳大利亚伦理委员会已批准其肥胖症药物植入物NPM-139的早期临床试验，该产品旨在随时间推移持续缓释药物** 称该试验将在20名成年受试者中进行，为期4周，旨在比较低剂量司美格鲁肽植入剂与Wegovy的疗效** 该试验将针对肥胖患者测试该植入剂，肥胖是一种因体内脂肪过多而增加患糖尿病和心脏病等疾病风险的病症** 公司表示，试验的主要目标是评估安全性及药物在体内的代谢情况，同时也会追踪体重减轻情况** 试验将于2026年年中启动；将根据结果筹备规模更大的后续研究** 截至上一交易日收盘，该股年内累计跌幅约为1%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646877499","isCrawlerRequest":true}